Literature DB >> 21153386

A case report of Sandhoff disease.

R Saouab, M Mahi, R Abilkacem, H Boumdin, S Chaouir, O Agader, T Amil, A Hanine.   

Abstract

Sandhoff disease is a rare and severe lysosomal storage disorder representing 7% of GM2 gangliosidoses. Bilateral thalamic involvement has been suggested as a diagnostic marker of Sandhoff disease. A case of an 18-month-old infant admitted for psychomotor regression and drug resistant myoclonic epilepsy is presented. Cerebral CT scan showed bilateral and symmetrical thalamic hyperdensity. MRI revealed that the thalamus was hyperintense on T(1)-weighted images and hypointense on T2-weighted images with a hypersignal T2 of the white matter. Enzymatic assays objectified a deficiency of both hexosaminidases A and B confirming the diagnosis of Sandhoff disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153386      PMCID: PMC3145082          DOI: 10.1007/s00062-010-0035-4

Source DB:  PubMed          Journal:  Clin Neuroradiol        ISSN: 1869-1439            Impact factor:   3.649


Introduction

Sandhoff disease is a rare but severe lysosomal storage disorder caused by a deficiency of both hexosaminidases A and B resulting in accumulation of glycosphingolipids and oligosaccharides in the brain. It represents 7% of cases of GM2 gangliosidosis. Bilateral thalamic involvement has been suggested as a diagnostic marker of Sandhoff disease but other structures such as basal ganglia, white matter and cerebellum can also be involved. In this article a new case of this disease with typical thalamic involvement is reported.

Observation

An 18-month-old boy born after an uncomplicated full-term pregnancy was hospitalized for psychomotor regression and drug-resistant myoclonic epilepsy. There was a consanguinity of the first degree of the parents and the death of a brother at the age of 16 months under unspecified circumstances. The other brother and sister were unaffected. The onset of clinical symptoms began at the age of 6 months with myoclonus of the face and upper limbs, recurrent fever and psychomotor developmental delay. Physical examination revealed a macrocephaly of 51 cm with a dysmorphic syndrome consisting of a frontal bossing and a broadening of the nasal bridge. The neurological examination revealed an axial hypotonia with no further optical problems or responsiveness to light. Ophthalmologic examination showed a cherry-red spot without optic atrophy. Cerebral computed tomography (CT) scanning performed without contrast medium injection showed a bilateral thalamic hyperdensity with hypodensity of the white matter (Fig. 1).
With magnetic resonance imaging (MRI) the thalamus was hyperintense on T1-weighted images and hypointense on T2-weighted images (Fig. 2) with an increased T2 signal of the white matter.
No imaging changes could be observed in the caudate nucleus, putamen, globus pallidum and brainstem. Clinical data and thalamic involvement suggest metabolic diseases such GM2 gangliosidosis (e.g. Tay-Sachs and Sandhoff diseases) or GM1 gangliosidosis (e.g. Landing disease), Canavan disease or Alexander disease. Chromatography of amino acids in the blood, urine and cerebrospinal fluid (CSF) was normal and chromatography of organic acids in the urine was also normal. Enzymatic assays were performed in France and revealed a deficiency of both hexosaminidases A and B confirming the diagnosis of Sandhoff disease.

Discussion

Sandhoff disease is a rare autosomal recessive inherited metabolic disorder caused by mutations in the HEXB gene on chromosome 5q13. It was first described by Konrad Sandhoff in 1968. There are three different forms of Sandhoff disease: classic infantile, juvenile and adult late onset. Classic infantile form is the most common and severe form, clinical onset is generally between 3 and 9 months of age after a normal development and is characterized by muscular hypotonia and tonico-clonic or myoclonic seizures, blindness, psychomotor retardation and paralysis [1]. A cherry-red spot in macular areas is characteristic but not specific. Juvenile and adult onset forms of Sandhoff disease are very rare. Signs and symptoms can begin in childhood, adolescence or adulthood and are usually milder than those seen with the infantile form of Sandhoff disease. No treatment is currently available and patients with infantile types usually die before 3 years of age [2]. Cerebral images of GM2 gangliosidosis have been published in a few reports and bilateral homogeneous thalamic hyperdensity on CT was reported to be an early sign [3]. Loss of axons and myelin in the central cortical neurons, gliosis and intralysosomal storage in addition to calcium accumulation might be responsible for this appearance [4]. Magnetic resonance imaging (MRI) typically reveals hypo-intensity in T2-weighted images of the thalamus [5] and high signal abnormalities have been reported in T2-weighted sequences in the caudate nucleus, globus pallidus and putamen [6]. Also the cerebral white matter shows homogenous or patchy high signal intensity which suggests a combination of disturbed and abnormal myelination and myelin loss. An unusual presentation of Sandhoff disease was reported by Nassogne et al. with diffuse signal changes exclusively in the brainstem of a 3-year-old girl [7]. Brainstem involvement appeared as a construction from the internal capsule involvement and descended downward along the long fiber tracts of the pons through the crus cerebri. Recently, Lowe et al. found an additional 2.07 ppm resonance in proton MRI spectra of the brain of Sandhoff mice which could be identified as originating from N-acetylhexosamine [8]. Wilken et al. reported similar proton MRS findings in a child with enzymatically proven Sandhoff disease. There was a reduction of total N-acetylaspartate (neuroaxonal marker) as well as strongly elevated inositol levels (glial marker) in white matter, gray matter and basal ganglia [9]. A decrease in T2 signal intensity in the thalami seems to be a sign of lysosomal diseases [10] and may also be identified in Tay-Sachs disease GM1 gangliosidoses and in late stages of Canavan disease or Krabbe’s disease. Patients with late stage Canavan disease may have dense thalami on T1-weighted images, as well as white matter necrosis, resulting in cavitation and brain stem and cerebellar atrophy, which are not observed in GM1 gangliosidoses. In Krabbe’s disease many more brain structures may demonstrate similar high density on CT and white matter disease is more extensive, more homogenous and does not spare the corpus callosum [4]. Diagnosis is confirmed by enzymatic assays revealing a deficiency of both lysosomal hydrolase β hexosaminidases A and B. In summary Sandhoff disease is a rare inherited lysosomal storage disorder characterized by thalamic hyperdensity which may be a useful sign for the differential diagnosis of neurodegenerative disorders with a cherry-red spot at the macula. Currently, proton magnetic resonance spectography (MRS) of cerebral metabolites may prove to represent another disease-specific MRS pattern of the brain.
  9 in total

1.  Neuroimaging findings of four patients with Sandhoff disease.

Authors:  A Yüksel; C Yalçinkaya; C Işlak; E Gündüz; M Seven
Journal:  Pediatr Neurol       Date:  1999-08       Impact factor: 3.372

2.  Unusual presentation of GM2 gangliosidosis mimicking a brain stem tumor in a 3-year-old girl.

Authors:  Marie-Cécile Nassogne; Marie-Christine Commare; Arielle Lellouch-Tubiana; Sophie Emond; Michel Zerah; Catherine Caillaud; Lucie Hertz-Pannier; Jean-Marie Saudubray
Journal:  AJNR Am J Neuroradiol       Date:  2003-05       Impact factor: 3.825

Review 3.  Juvenile Sandhoff disease--nine new cases and a review of the literature.

Authors:  C J Hendriksz; P C Corry; J E Wraith; G T N Besley; A Cooper; C D Ferrie
Journal:  J Inherit Metab Dis       Date:  2004       Impact factor: 4.982

4.  MRS reveals additional hexose N-acetyl resonances in the brain of a mouse model for Sandhoff disease.

Authors:  J P Lowe; D J Stuckey; F R Awan; M Jeyakumar; D C A Neville; F M Platt; J L Griffin; P Styles; A M Blamire; N R Sibson
Journal:  NMR Biomed       Date:  2005-12       Impact factor: 4.044

5.  MRI in a case of Sandhoff's disease.

Authors:  K Hittmair; D Wimberger; G Bernert; R Mallek; E G Schindler
Journal:  Neuroradiology       Date:  1996-05       Impact factor: 2.804

6.  [Evolutive neuroradiological alterations in Sandhoff's disease].

Authors:  L G Gutiérrez-Solana; M L Ruiz-Falcó; J J García-Peñas; A Chabás; S Manzano-Blanco; G Gómez-Mardones; J M López-Terradas
Journal:  Rev Neurol       Date:  1996-10       Impact factor: 0.870

Review 7.  Decreased T2 signal in the thalami may be a sign of lysosomal storage disease.

Authors:  Taina Autti; Raimo Joensuu; Laura Aberg
Journal:  Neuroradiology       Date:  2007-03-03       Impact factor: 2.804

8.  GM-2 gangliosidosis (Sandhoff's disease): two year follow-up by MRI.

Authors:  W Koelfen; M Freund; W Jaschke; S Koenig; C Schultze
Journal:  Neuroradiology       Date:  1994       Impact factor: 2.804

9.  Proton MRS of a child with Sandhoff disease reveals elevated brain hexosamine.

Authors:  B Wilken; P Dechent; F Hanefeld; J Frahm
Journal:  Eur J Paediatr Neurol       Date:  2007-07-10       Impact factor: 3.140

  9 in total
  6 in total

Review 1.  Emergencies in motoneuron disease.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Intern Emerg Med       Date:  2017-03-09       Impact factor: 3.397

2.  TSPO in a murine model of Sandhoff disease: presymptomatic marker of neurodegeneration and disease pathophysiology.

Authors:  Meredith K Loth; Judy Choi; Jennifer L McGlothan; Mikhail V Pletnikov; Martin G Pomper; Tomás R Guilarte
Journal:  Neurobiol Dis       Date:  2015-11-03       Impact factor: 5.996

3.  An Infantile Case of Sandhoff Disease Presenting With Swallowing Difficulty.

Authors:  Jae-Gun Moon; Min-A Shin; Hannah Pyo; Seong-Uk Choi; Hyun-Kyung Kim
Journal:  Ann Rehabil Med       Date:  2017-10-31

4.  Decrease in Myelin-Associated Lipids Precedes Neuronal Loss and Glial Activation in the CNS of the Sandhoff Mouse as Determined by Metabolomics.

Authors:  Emmanuelle Lecommandeur; Maria Begoña Cachón-González; Susannah Boddie; Ben D McNally; Andrew W Nicholls; Timothy M Cox; Julian L Griffin
Journal:  Metabolites       Date:  2020-12-30

5.  Infantile Sandhoff disease with ventricular septal defect: a case report.

Authors:  Jamal Khaled Sahyouni; Luma Bassam Mahmoud Odeh; Fahad Mulla; Sana Junaid; Subhranshu Sekhar Kar; Naheel Mohammad Jumah Al Boot Almarri
Journal:  J Med Case Rep       Date:  2022-08-25

6.  Alterations in endo-lysosomal function induce similar hepatic lipid profiles in rodent models of drug-induced phospholipidosis and Sandhoff disease.

Authors:  Emmanuelle Lecommandeur; David Baker; Timothy M Cox; Andrew W Nicholls; Julian L Griffin
Journal:  J Lipid Res       Date:  2017-04-04       Impact factor: 5.922

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.